.png "Global Insight")
For doctors treating the world's most common genetic blood disorder, one fear has long held back a cheap, effective drug: could hydroxyurea, which dampens the immune system, make children with sickle cell anemia more vulnerable to deadly infections? A landmark 10-year trial across four African countries has now answered that question with data. The answer, published in The Lancet Haematology and reported by Medical Xpress, is no — and infections actually fell as doses rose.
The REACH trial, by the numbers
The trial, known as REACH, enrolled 606 children and young adults with sickle cell anemia at four sites: Angola, the Democratic Republic of the Congo, Kenya and Uganda. Recruitment of children aged one to ten took place between 2014 and 2016, and patients were followed every two to three months for over a decade — more than 5,000 patient-years of follow-up. Children began hydroxyurea at a fixed dose for six months, then were escalated to the maximum dose they could tolerate. The results: the risk of infection dropped by 51% for malaria and 38% for non-malarial infections as hydroxyurea doses increased, and there was no increase in illness or death from infections — even at the maximum tolerated dose.
Why the fear mattered
The caution was understandable, especially in low-income settings with limited medical resources. 'Many doctors are cautious about using hydroxyurea because they are worried that it will increase the risks of severe or fatal infections,' said study lead Prof. Tom Williams of Imperial College London's Institute of Global Health Innovation, in comments reported by Medical Xpress. REACH had already shown the drug is safe and highly effective at reducing most sickle-cell complications; this extended analysis closes the last big safety gap. The authors now recommend that children with sickle cell anemia in low-resource settings receive hydroxyurea at the maximum tolerated dose — supporting its wider use as standard care.
An equity story, not just a drug story
The stakes are enormous. An estimated 300,000 to 400,000 babies are born with sickle cell disease in sub-Saharan Africa each year, and without care roughly half do not survive to age 10 — while in the US, widespread newborn screening and treatment have pushed life expectancy past 50. Hydroxyurea costs little compared with new gene therapies, and this trial, conducted exactly where the burden is heaviest, removes the main argument against using it there. The weak link now is not evidence but delivery: getting an affordable, proven drug to the clinics that need it most.
This article is general information only and is not medical advice.
Follow Global Insight for the health stories that matter.